Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Vella Bioscience Launches Ebbtide™, A Science-Driven Vaginal Insert Designed to Address the Source of Menstrual Discomfort

      Vella Bioscience Logo (PRNewsfoto/Vella Bioscience)

      News provided by

      Vella Bioscience

      May 12, 2026, 09:00 ET

      Share this article

      Share this article


      Bringing a clinically validated, non-hormonal approach to menstrual discomfort, Vella's newest innovation targets the biological source of cramping, not just the symptoms

      NEW YORK, May 12, 2026 /PRNewswire/ -- For too long, menstrual discomfort has been undertreaded and left without real solutions. Today, Vella Bioscience is changing that, with the launch of Ebbtide™, the brand's first vaginal insert designed to support comfort and ease the physical discomfort associated with menstruation and pelvic tension. The launch marks a significant expansion of Vella's complete women's wellness system deepening its mission to close the persistent gaps in women's health research, education, and care. Ebbtide is available starting May 19th, priced at $25 for a four-pack and $42 for an eight-pack; subscribers receive 20% off with a monthly subscription.

      Continue Reading
      Vella Bioscience - Ebbtide 1 (hero)
      Vella Bioscience - Ebbtide 1 (hero)
      Vella Bioscience - Ebbtide 2 (packaging)
      Vella Bioscience - Ebbtide 2 (packaging)

      Developed by the same team behind Viagra® and Cialis®, Ebbtide is built on a simple but powerful premise: that menstrual discomfort deserves the same scientific rigor applied to every other area of sexual health. This vaginal insert formulation is validated through rigorous preclinical and mechanistic studies to support uterine muscular relaxation, working at the physiological source of cramping and tension, rather than masking the symptoms.

      "Menstrual and pelvic discomfort are often minimized or normalized, but they shouldn't be," said Dr. Maria Uloko, MD, board-certified urologist, women's sexual health specialist, and member of Vella's Scientific Advisory Board. "Ebbtide is different because it works at the physiological source of cramping and tension. The underlying science - developed by Vella's R&D team - focuses on reducing uterine contractility through a novel combination of CBD and CBDA. That scientific rigor translates into real-world impact: meaningful options for women navigating menstrual discomfort, and more control over their daily lives."

      In clinical trials, 81% of women reduced or eliminated their use of oral medications while using Ebbtide, positioning it as a meaningful, localized, non-hormonal option for women seeking greater comfort and control during their cycle.

      Ebbtide™ - Key Product Highlights:

      • A targeted approach to menstrual and pelvic discomfort. Unlike oral medications that work systemically, Ebbtide is a vaginal suppository that delivers active support directly where women experience discomfort, offering localized comfort that systemic options often can't replicate.
      • Formulated to melt into the body. A base of high-purity coconut-derived lipids, lauric-acid–derived lipids, glycerides, and macrogol esters allows Ebbtide to dissolve cleanly into the vaginal canal, delivering its active ingredients at the tissue level and soothing delicate tissue from within.
      • Powered by highly purified CBD isolate via CPTv1™, Vella's proprietary cannabidiol precision technology - delivering a consistent, reliable dose free from the variability, odor, or extraneous compounds often associated with full-spectrum extracts.
      • Vitamin E for tissue care. Vitamin E supports the body's natural conditioning processes, calming and nourishing intimate tissue as discomfort eases.
      • Built for more than your cycle. Pelvic tension is common across perimenopause, menopause, and postpartum recovery. Ebbtide's muscle-calming, tissue-soothing formula supports ease and comfort through hormonal shifts at every stage of life.

      "Ebbtide brings our founding vision to life," said Carolyn Wheeler, Co-Founder and CEO of Vella Bioscience."It's the belief that women deserve science built around them, at every stage of their lives. From menstruation to menopause, too much has been left unaddressed for too long.  Vella is here to serve women more holistically, across the full arc of their lives, with dignity and evidence-based care."

      As part of our commitment to expanding access to menstrual care, Vella is also announcing a partnership with PERIOD., a global nonprofit dedicated to ending period poverty and stigma. In recognition of Menstrual Hygiene Day on May 28, Vella will make a $15,000 cash donation to support PERIOD.'s ongoing efforts to increase access to menstrual products and education worldwide.

      "Access to menstrual care is fundamental, yet so many people still lack the resources they need to manage their cycles with dignity," said Jennifer Herrera, Executive Director of PERIOD. "We're excited to partner with Vella to expand access to care , including innovative solutions like Ebbtide that are designed to ease pelvic discomfort during menstruation. This partnership helps us continue our work to ensure that more of our PERIOD. leaders have access not just to basic products, but to meaningful support for their menstrual health."

      In addition, Vella is launching an ongoing giveback model tied to Ebbtide subscriptions. For every Ebbtide subscription purchased, Vella will donate a menstrual care kit - including an Ebbtide 8-pack and essential supplies - to PERIOD.'s university chapter leaders across the country, with a commitment of up to $15,000 in product annually over the next three years.

      "At Vella, we believe innovation only matters if it reaches women in real life," said Joy Allen-Altimare, President of Vella Bioscience. "This partnership is about ensuring that access to care evolves alongside the science—so that more women, regardless of circumstance, can experience greater comfort, agency, and support throughout their cycle."

      Ebbtide™ will be available for purchase starting May 19, 2026 at www.vellabio.com, priced at $25 for a four-pack and $42 for an eight-pack. Subscribers receive 20% off with a monthly subscription. For more information, visit www.vellabio.com. 

      About Vella Bioscience, Inc.
      Vella Bioscience, Inc. is a female health innovator dedicated to advancing women's sexual, hormonal, and intimate wellness through rigorous science and proprietary biotechnology. Built on scientific rigor and developed by the same team behind Viagra® and Cialis®, Vella addresses critical gaps in women's health research with products designed to empower women through education and evidence-based care. The company launched the category-first Vella Pleasure Serum, giving women unprecedented agency over their sexual experiences through a science-backed, hormone-free approach. To learn more, visit www.vellabio.com.

      About PERIOD. 
      PERIOD is a global, youth-powered organization working to end period poverty and stigma through advocacy, education, and service. PERIOD. helps promote laws and policies that make period products affordable and accessible, authors original menstrual health curriculum and resources, and distributes millions of period products annually. Learn more at period.org.

      Media Contact: [email protected]

      SOURCE Vella Bioscience

      Modal title

      Also from this source

      Vella Bioscience Brings Precision to CBD With Pleasurewave™

      Vella Bioscience Brings Precision to CBD With Pleasurewave™

      Though conversations around women's pleasure are slowly opening up, the gap between awareness and access remains. Most "solutions" designed to...

      Vella Bioscience Reveals Bold Rebrand - An Unapologetic Approach to Championing Women's Sexual Vitality and Hormonal Wellness

      Vella Bioscience Reveals Bold Rebrand - An Unapologetic Approach to Championing Women's Sexual Vitality and Hormonal Wellness

      Vella Bioscience, a pioneering female health company advancing clinically driven solutions in women's hormonal, sexual, and intimate health, today...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Cosmetics and Personal Care

      Cosmetics and Personal Care

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Household, Consumer & Cosmetics

      Household, Consumer & Cosmetics

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.